コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 hibition with a CCD inhibitor (MUXF(3)-human serum albumin).
2 to lysines 195 and 475 of CLV-treated human serum albumin.
3 ermined that ATRAM binds reversibly to human serum albumin.
4 arance half-life through enhanced binding to serum albumin.
5 ion of a pendant maleimide ligand with human serum albumin.
6 n levels as well as significant reduction of serum albumin.
7 h forms a high molecular weight complex with serum albumin.
8 Disease, Hispanic race, older age and a low serum albumin.
9 ic binding of bovine serum albumin and human serum albumin.
10 e chromatography based purification of human serum albumin.
11 sis of peptides from trypsin digested bovine serum albumin.
12 coli cells and does not interact with bovine serum albumin.
13 ne-derivatized fluorophore-conjugated bovine serum albumin.
14 tibody fragment specific for mouse and human serum albumin.
15 glycine, and beta-mercaptoethanol) and human serum albumin.
16 n, beta-lactoglobulin, soy protein and human serum albumin.
17 inding capacity, transferrin saturation, and serum albumin.
18 m was measured at baseline and corrected for serum albumin.
19 f binding between the lipidated peptides and serum albumin.
20 n combination of calcium alginate and bovine serum albumin.
21 r secretion without the presence of serum or serum albumin.
22 blood was removed and replaced with 5% human serum albumin.
23 y defined albumin supplements such as bovine serum albumin.
24 spiked in a protein digest mixture of bovine serum albumin.
25 oparticles in ethanolic solutions and bovine serum albumin.
26 olled hydrolysis and precipitation of bovine serum albumin.
27 tion calorimetry that JMS-053 binds to human serum albumin.
28 known to exhibit high binding affinities to serum albumin.
29 nt in fetal bovine serum (FBS) identified as serum albumin.
30 unfolding pathway for a group of homologous serum albumins.
32 treatment, were neutropenia (48 [15%]), low serum albumin (33 [10%]), weight loss (29 [9%]), and ana
33 measured charge-state distribution of bovine serum albumin (66.5 kDa), indicating that ion-ion intera
35 mpletely removes p-cresyl sulfate from human serum albumin, a protein that these uremic toxins bind t
36 th was evaluated, and FITC conjugated bovine serum albumin across monolayer hRECs served as an index
38 dy mass index, haemoglobin, serum uric acid, serum albumin, albuminuria, and C reactive protein as no
39 49 T, 37 degrees C) in the presence of human serum albumin, allowing a significant MRI signal intensi
42 he screening tools, length of hospital stay, serum albumin and cholesterol concentrations, lymphocyte
43 clusters (AuQC@BSA) synthesized using bovine serum albumin and conjugated with acetylcholinesterase (
44 demonstrate protein binding by using bovine serum albumin and detection of antibody-antigen immune r
45 e the morphology of hydrogels made of bovine serum albumin and gelatin following high pressure proces
47 to differentially charged epitopes on mouse serum albumin and human epidermal growth factor receptor
49 S, combining elevated hsCRP and ESR with low serum albumin and iron], and serum interleukin (IL) 1bet
52 the pressure effect was performed for bovine serum albumin and thyroglobulin that required gradient s
53 ison of lipid binding to the soluble protein serum albumin and to the integral membrane protein NapA
54 minor (lactoferrin, lactoperoxidase, bovine serum albumin) and major (alpha-lactalbumin, beta-lactog
57 cluding elongation factor 1-alpha1 and mouse serum albumin, and found that iTORC reliably detected th
59 opylene glycol (PPG), angiotensin II, bovine serum albumin, and the "thermometer" compound p-methoxyb
60 ed via the covalent immobilization of bovine serum albumin antibody (anti-BSA) and fibrinogen antibod
62 Chitosan capped gold nanoparticles on bovine serum albumin are proposed as an ultrasensitive plasmoni
64 ing sulforhodamine b, zidovudine, and bovine serum albumin as model hydrophilic drugs, we found tappe
65 elated characteristics (high MELD score, low serum albumin, ascites, encephalopathy), surgery-related
66 identified by X-ray crystallography in human serum albumin at drug site 3, which is also known as sub
68 ent of supercharging was probed using bovine serum albumin, beta-lactoglobulin, and lysozyme, each of
71 ptide, which lies in Subdomain IIIA of human serum albumin, blocks binding of all three antibodies to
72 deficiency virus status with CD4 count, age, serum albumin, body mass index, and pre-existing hearing
75 ns including cardiac myoglobin (MYG), bovine serum albumin (BSA) and cardiac troponin T (cTnT), respe
77 ace properties with various proteins (bovine serum albumin (BSA) and different forms of hemoglobin).
78 y (PPC) using two different proteins [bovine serum albumin (BSA) and gelatin], molecular weights, tot
79 nd biodegradability, albumins such as bovine serum albumin (BSA) and human serum albumin (HSA) have f
80 on behavior of two model proteins- i) bovine serum albumin (BSA) and ii) beta-galactosidase (beta-gal
82 shells comprising alternate layers of bovine serum albumin (BSA) and tannic acid (TA) were tested as
83 sp.) hydrolyzed iron oxide-associated bovine serum albumin (BSA) and the factors that affected the pr
84 roach with a 4-plex labeled sample of bovine serum albumin (BSA) and yeast lysates mixed at different
85 mug/mL) after passive adsorption and bovine serum albumin (BSA) as a blocking agent generated a mode
87 ly by a bichinchonic acid assay using bovine-serum albumin (BSA) as a protein model on the l-cysteine
89 es of insulin, alpha-lactalbumin, and bovine serum albumin (BSA) as well as the free C34-BSA were dem
90 ted the interaction of CA and MC with bovine serum albumin (BSA) at pH 3.5, 5.0, and 7.4 using fluore
92 of protein-based hydrogels made from bovine serum albumin (BSA) by using polyelectrolytes such as po
93 tein Fluorescein isothiocynate (FITC) Bovine Serum Albumin (BSA) conjugate incorporated in the sheath
94 ata were collected from a solution of bovine serum albumin (BSA) digested by trypsin as an enzymatic
97 results of HS-SPME/GC indicated that bovine serum albumin (BSA) had the highest affinity toward safr
98 the mechanism of SA interaction with bovine serum albumin (BSA) has been investigated by multi-spect
99 ent and in vitro release behaviour of bovine serum albumin (BSA) in chitosan-tripolyphosphate (TPP) h
100 t's Reagent (TR) was used to thiolate Bovine serum albumin (BSA) in solution followed by chemical cro
101 he migration of fluorescently labeled bovine serum albumin (BSA) into the nanoslits; and fluorescence
103 endent adsorption and denaturation of bovine serum albumin (BSA) protein onto a silica-coated array o
104 ient way; LC-MS of a trypsin-digested bovine serum albumin (BSA) sample provided narrow peaks, short
105 biocompatible nanocomposite including bovine serum albumin (BSA) template Cu nanoclusters (CuNCs@BSA)
106 s demonstrated that the adsorption of bovine serum albumin (BSA) to aqueous gold colloids can be quan
107 We illustrate a method that uses bovine serum albumin (BSA) to control the receptor-accessible p
108 lay important roles in the ability of bovine serum albumin (BSA) to form stable nanostructures with b
109 even when the molar ratio of IgG and bovine serum albumin (BSA) tryptic digest mixtures reached to 1
110 As a case study, we choose to monitor bovine serum albumin (BSA) unspecific adsorption, which has bee
114 -3-glucoside (CYG) through binding to bovine serum albumin (BSA) was investigated at pH 3.0 using ato
116 he interaction between Allura Red and bovine serum albumin (BSA) was studied in vitro at pH 7.4.
117 immobilized via EDC-NHS chemistry and Bovine serum albumin (BSA) was used for blocking of the non-spe
118 ), alpha-lactalbumin (alpha-Lac), and bovine serum albumin (BSA) were bound to beta-C with overall bi
120 ion followed by a post-treatment with bovine serum albumin (BSA) which served as the blocking agent t
121 tudy, we evaluated the interaction of bovine serum albumin (BSA) with AP and AS using surface plasmon
122 this report, a stepwise unfolding of bovine serum albumin (BSA) with guanidine hydrochloride (GuHCl)
123 psin Inhibitor (TI); Ovalbumin (OVA); Bovine Serum Albumin (BSA)), we observe resolution of the marke
124 -plant leaves at different rates with bovine serum albumin (BSA), a molecular substitute for detritus
125 Compared to Y-tube compartments with bovine serum albumin (BSA), GDNF and NGF increased the motor an
126 mplex with a model transport protein, bovine serum albumin (BSA), have been explored by means of diff
127 h on albumin hydrogels has focused on bovine serum albumin (BSA), leaving human serum albumin (HSA) c
128 roteins including chymotrypsin (chy), bovine serum albumin (BSA), lysozyme (lyz) and cytochrome c (cy
129 deposited gold film and adsorption of bovine serum albumin (BSA), respectively, on poly(methyl methac
138 ontaining small (glycerol) and large (bovine serum albumin; BSA) analyte molecules, indicating that t
139 e, sex, time from diagnosis, proteinuria, or serum albumin, but epitope spreading strongly correlated
140 ng affinity between drug molecules and human serum albumin by combining nanoporous anodic alumina rug
141 Further studies are required to confirm that serum albumin can be used as a biomarker to monitor dise
142 he biomimetic nanoparticles (cationic bovine serum albumin (CBSA) conjugated siS100A4 and exosome mem
143 ion strategy based on carbon nanotube-bovine serum albumin (CNT-BSA) hybrid system, by which sensitiv
144 We report the crystal structures of equine serum albumin complexed with four NSAIDs (ibuprofen, ket
147 sclerosis on initial biopsy as well as age, serum albumin concentration, and CKD stage at onset affe
149 d on the quantitation of extravasated bovine serum albumin conjugated to Evans Blue, as an indicator
153 es of the enrichment step from spiked bovine serum albumin digests were >80% for the commercial Fe-IM
154 as densely immobilized conjugates of bovine serum albumin (DNP-BSA) or mobile in a supported lipid b
159 tochrome c, ubiquitin, myoglobin, and bovine serum albumin formed by electrospray ionization are meas
160 A aptamers specifically bound glycated human serum albumin (GHSA), which is an intermediate marker fo
161 h four reference molecules (dopamine, bovine serum albumin, glucose and elongated peptide) was neglig
162 Centella asiatica phenolics (CAP) on bovine serum albumin glycoxidation in a BSA-glucose model in vi
163 eting highly abundant proteins such as human serum albumin (>10(10) more abundant than cTnI).
165 related was associated with older age, lower serum albumin, higher blood neutrophil counts, and great
167 rement (LSM) (HR 1.040; 95% CI 1.017-1.064), serum albumin (HR 0.400; 95% CI 0.174-0.923), 1-year Del
168 R = 1.8; 95% CI = 1.2-2.6; P < 0.01) and low serum albumin (HR = 2.1; 95% CI = 1.5-2.9; P < 0.01) wer
169 simple post-adsorption of human serum:bovine serum albumin (HS:BSA) mixtures onto the folic acid modi
171 as high as 7-fold increase versus the human serum albumin (HSA) and 8-fold increase versus the human
172 pH-dependent conformational changes in human serum albumin (HSA) and cytochrome C by monitoring cross
173 towards the target biomarker proteins (human serum albumin (HSA) and human immunoglobulin G (HIgG)) a
174 rugate filters (NAA-RFs) modified with human serum albumin (HSA) and reflectometric interference spec
175 namics and kinetics of binding between human serum albumin (HSA) and resveratrol (RES) or its analog
177 dy was to investigate the potential of human serum albumin (HSA) as a solubilising agent/drug deliver
178 e of a high concentration (500 muM) of human serum albumin (HSA) as an interfering protein in the bac
180 ghly disulfide-bonded proteins such as human serum albumin (HSA) by online EC reduction of nonreduced
184 noparticle (SPNP) based on polymerized human serum albumin (HSA) equipped with the cell-penetrating p
186 such as bovine serum albumin (BSA) and human serum albumin (HSA) have found a wide range of biomedica
187 profiled adducts at the Cys34 locus of human serum albumin (HSA) in 29 nonsmoking Xuanwei and Fuyuan
191 uantitative and selective detection of human serum albumin (HSA) is demonstrated with a limit of dete
192 as detected on four lysine residues of human serum albumin (HSA) isolated from tolerant patients.
193 for PSMA and appropriate affinity for human serum albumin (HSA) may demonstrate a higher therapeutic
194 we loaded ATO onto folate (FA)-labeled human serum albumin (HSA) pretreated with glutathione (GSH) ba
195 olution chemistry on the adsorption of human serum albumin (HSA) proteins on graphene oxide (GO) was
196 d (SM) produces a covalent adduct with human serum albumin (HSA) representing an established plasma b
198 etermined binding affinity of DOX with human serum albumin (HSA) was considered to simplify the mathe
199 e (FITC) after fluorescent labeling of human serum albumin (HSA) with electromembrane extraction (EME
201 complexes with albumin (in particular, human serum albumin (HSA)) are fundamental for the characteriz
202 glutathione S-transferase pi (hGSTP), human serum albumin (HSA), and bovine serum albumin (BSA) as m
204 antly expressed extracellular protein, human serum albumin (HSA), inhibits alphaS oligomer (alphaS(n)
205 he presence of physiological levels of human serum albumin (HSA), the r(1) relaxivity is amplified fu
206 inhibitor of Abeta self-association is human serum albumin (HSA), which binds approximately 90% of pl
207 s, we rationally developed a drug-free human serum albumin (HSA)-based therapeutic (KH-1) that functi
217 ant delivery systems (liposomes and in human serum albumin [HSA]-fusion products) in combination with
218 bining administration of an engineered mouse serum albumin/IL-2 fusion with an Fc fusion to an integr
220 ious membrane transporters, association with serum albumin in circulatory and extracellular spaces, a
222 ion, reduced ESA requirements, and increased serum albumin in patients on hemodialysis with inflammat
224 rtisol solutions in a complex matrix (bovine serum albumin in phosphate buffered saline) is also demo
226 lysozyme and all 17 disulfide bonds in human serum albumin, including nested disulfide bonds and moti
229 m dissociation constant for Zn(2+) and human serum albumin (Kd = (5.62 +/- 0.93) x 10(-7) M) under ph
230 lue resulted in sustained improvement of the serum albumin level and symptoms in 3 patients, temporar
231 lbumin level than men, and stratification by serum albumin level attenuated sex differences in the ag
232 ing treatment with IVIG (2 g/kg), the median serum albumin level decreased to 3.7 g/dL (interquartile
233 el of 82 g/L (reference range, 66-81 g/L), a serum albumin level of 39.3 g/L (reference range, 40.2-4
236 rum bilirubin, 22.2 mg/dL), hypoalbuminemia (serum albumin level, 2.58 g/dL), coagulopathy (prothromb
238 sitive unlike normal Fc interactions and how serum albumin levels are unaffected by DX-2507 binding.
241 sess whether there is an association between serum albumin levels, a widely used and relatively easil
244 Conjugation of fatty acid, a natural human serum albumin ligand, to a therapeutic protein/peptide w
249 f non-nephrotic range proteinuria (NNRP) and serum albumin measurements in relation to PLA2R-AB statu
250 ment of the particle supernatant with bovine serum albumin mitigates the negative effects of free or
253 however, ion mobility resolution for bovine serum albumin (MW ~ 68 kDa) is less than ~20, which aris
254 than 95% of model biochemical species (human serum albumin, neurotensin, creatinine, glycine, and ala
256 8 (MMP-8), minocycline hydrochloride, bovine serum albumin, or an antibacterial peptide (KSL) was inc
259 gh doses (1.5 g/kg every week) of albumin on serum albumin, plasma renin, cardiocirculatory function,
260 suggest that oxo-amino-acids of the protein serum albumin play a major role in the translocation of
262 alent binding of biopharmaceuticals to human serum albumin protects against enzymatic degradation and
263 patinib release from a nanoshell-based human serum albumin protein host complex resulted in increased
265 evaluating the cerebrospinal fluid (CSF) to serum albumin quotient (QAlb) in patients with primary H
266 oteric compounds, such as hemoglobin, bovine serum albumin, R-phycoerythrin, and histidine, within mi
267 emodin and aloe-emodin derivatives to human serum albumin ranged from -7.30 and -10.62 kcal/mol.
269 vels of K212Hcy and K525Hcy modifications in serum albumin relative to their female (n = 19) and male
270 ounds (sucrose, dopamine, starch, and bovine serum albumin), resulting in negligible cross-reactivity
271 and positive co-protein effects with bovine serum albumin, (S-)ovalbumin, egg white, whole egg, defa
272 es and spleen of a systemically administered serum albumin (SA)-IL-4 fusion protein leads to higher e
274 The plasmonic construct consists of a bovine serum albumin scaffold with approximately 210 IRDye 800C
275 ctivity 1:400 horse radish peroxidase/bovine serum albumin, sensitivity to 100 attomoles, recovery 89
276 ated using IDA in intact and digested bovine serum albumin solutions using the TCN (98 and 100%, resp
277 tate on structures of native-like cations of serum albumin, streptavidin, avidin, and alcohol dehydro
278 nsional porous matrix of cross-linked bovine serum albumin supported by a network of conductive nanom
279 l as a functionally superior replacement for serum albumin that is compatible with good manufacturing
281 blood was removed and replaced with 5% human serum albumin to reduce haemoglobin concentration (n = 8
283 the intrinsic transport properties of human serum albumin to tune the blood circulatory half-life, h
285 e, we examine the binding of an ABD to human serum albumin using isothermal titration calorimetry and
286 (GSC) and PT uptake of Texas Red-labeled rat serum albumin using two-photon intravital microscopy.
290 re, the interaction between KP1019 and human serum albumin was investigated by means of X-ray crystal
294 sing is inhibited by physiological levels of serum albumin, which appears to bind and sequester some
295 tase 4A3 binds to at least one site on human serum albumin, which is likely to extend the compound's
296 e focused on modifications to Cys34 in human serum albumin, which is responsible for scavenging small
297 blood proteins, particularly Cys34 of human serum albumin, which is the dominant scavenger of reacti
298 -specific antibody linked in tandem to human serum albumin, which retained FcgammaR-binding activity
299 ibody binding site, HSA Peptide 40, on human serum albumin with nanomolar affinity for all three mono
300 ically adsorbed films of the protein, bovine serum albumin, with different alpha-helix and beta-sheet